Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on December 8, 2025, and filed on December 9, 2025. The filing details a share repurchase executed through BNP Paribas SA as part of an existing buyback programme established via a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchases rather than operational financial performance.
- Shares Purchased (Dec 8, 2025): 229,000 ordinary shares.
- Price Range: Lowest 1,803.00p; Highest 1,822.00p.
- Volume-Weighted Average Price (VWAP): 1,814.42p.
- Accumulated Buyback (Since Sept 30, 2025): 12,474,733 ordinary shares.
- Treasury Shares Held: 237,939,577 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,077,499,560 ordinary shares.
- Voting Rights in Treasury: 5.84% of total voting rights.
Material Changes
There are no material changes to revenue, profit, or operational metrics reported in this filing. The primary change is the reduction of shares in issue and the increase in treasury shares following the December 8 transaction. The total number of voting rights remains 4,077,499,560, which serves as the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q3 2025 Results. The purchase was executed pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total number of shares in issue (4,077,499,560) for calculating ownership percentages and disclosure thresholds.
- Confirm the percentage of voting rights held in treasury (5.84%) to assess potential dilution or voting power dynamics.
- Review the September 30, 2025 announcement to understand the total authorized size and duration of the current buyback programme.
- Check the 2024 Form 20-F and Q3 2025 results for the risk factors referenced in the cautionary statement.